WEKO3
アイテム
子宮体部漿液性がん腹膜播種に対する標的アルファ線治療の前臨床研究
https://repo.qst.go.jp/records/85936
https://repo.qst.go.jp/records/85936716db3bb-4b6d-452f-b5c1-912b832e7d39
| Item type | 会議発表用資料 / Presentation(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2022-04-08 | |||||
| タイトル | ||||||
| タイトル | 子宮体部漿液性がん腹膜播種に対する標的アルファ線治療の前臨床研究 | |||||
| 言語 | ||||||
| 言語 | jpn | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||
| 資源タイプ | conference object | |||||
| アクセス権 | ||||||
| アクセス権 | metadata only access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
| 著者 |
李, 惠子
× 李, 惠子× 安康, 真由香× 長谷川, 純崇× Li, Huizi× Mayuka, Anko× Sumitaka, Hasegawa |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | Uterine serous carcinoma (USC) is a rare aggressive type 2 endometrial carcinoma with high recurrence rate and dismal prognosis. Peritoneal metastasis is one of the common metastases of USC. Although trastuzumab, the anti-HER2 antibody, has shown benefit in the treatment of HER2 positive USC, the therapeutic efficacy is still limited. Targeted alpha therapy (TAT) has high potential as a promising therapeutic option for metastasis. Astatine 211 (At-211) is one of the attractive α-particle emitters with an appropriate half-life and producible with cyclotron. We have demonstrated experimental TAT using [At-211]trastuzumab to preclinical mouse model with peritoneal metastasis of HER2 positive USC in order to investigate the therapeutic efficacy and toxicity. We will discuss the potential of TAT as a novel therapeutic option for peritoneal metastasis of HER2 positive USC. | |||||
| 会議概要（会議名, 開催地, 会期, 主催者等） | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | 第61回日本核医学会学術総会 | |||||
| 発表年月日 | ||||||
| 日付 | 2021-11-05 | |||||
| 日付タイプ | Issued | |||||
